Introduction {#s1}
============

Aspirin (acetylsalicylic acid, ASA) and nonsteroidal antiinflammatory drugs (NSAIDs) are the most commonly prescribed drugs in the world ([@B24]); however, they are considered the most common causes of hypersensitivity reactions to drugs ([@B4]). Hypersensitivity reactions to NSAIDs have recently been classified by the European Academy of Allergy and Clinical Immunology (EAACI) and European Network of Drug Allergy (ENDA): 1) pharmacologic reactions (mediated by cyclooxygenase \[COX\]-1 inhibitions) include NSAID-exacerbated respiratory disease (NERD), NSAID-exacerbated cutaneous disease (NECD) and NSAID-induced urticarial/angioedema (NIUA), and present cross-intolerance to various COX-1 inhibitors; 2) selective responses (mediated by immunologic mechanisms) include single NSAIDs-induced urticaria, angioedema and/or anaphylaxis (SNIUAA) and single NSAIDs-induced delayed hypersensitivity reactions (SNIDHR) ([@B45]). NERD is a major phenotype among cross-intolerant categories of NSAID hypersensitivity and had been called ASA-induced asthma, ASA-intolerant asthma, ASA-sensitive asthma; however, NERD and ASA-exacerbated respiratory disease (AERD) are commonly used ([@B79]). The prevalence of NERD is reported to be 5.5% to 12.4% in the general population ([@B56]; [@B19]; [@B92]), 7.1% among adult asthmatics and 14.9% among severe asthmatics ([@B73]), while it rarely occurs in children ([@B92]). No relationships were found with family history or NSAID administration history ([@B47]; [@B92]).

NERD is characterized by moderate-to-severe asthma and a higher prevalence of chronic rhinosinusitis (CRS) nasal polyps (NPs) with persistent eosinophilic inflammation in the upper and lower airways ([@B92]) as well as NSAID hypersensitivity where cysteinyl leukotrienes (CysLTs) over-production and chronic type 2 airway inflammation are key findings ([@B92]). The diagnosis of NERD is confirmed by ASA challenge (*via* orally, bronchially or nasally route) and supported by potential biomarkers ([@B71]; [@B20]). In addition, *in vitro* cell activation tests and radiological imaging with nasal endoscopy can aid in NERD diagnosis ([@B92]). This review updates the current knowledge on pathophysiologic mechanisms including molecular genetic mechanisms as well as the diagnosis and treatment of NERD.

Clinical Features {#s2}
=================

NERD is characterized by chronic type 2 inflammation in the upper and lower airways; therefore, patients suffer from chronic persistent asthmatic symptoms and CRS with/without NPs, which are exacerbated by ASA/NSAID exposure and refractory to conventional medical or surgical treatment. Some patients are accompanied by cutaneous symptoms such as urticaria, angioedema, flushing or gastrointestinal symptoms ([@B7]). Previous studies suggested that NERD is more common in females (middle-age onset) and non-atopics ([@B15]; [@B93]). It was reported that rhinitis symptoms appear and then evolve into CRS which worsens asthmatic symptoms, subsequently followed by ASA intolerance ([@B89]). However, their clinical presentations and courses have been found to be heterogeneous. It has been increasingly required to classify the subphenotypes of NERD according to its clinical features. One study demonstrated 4 subphenotypes by applying a latent class analysis in a Polish cohort: class 1 patients showing moderate asthma with upper airway symptoms and blood eosinophilia; class 2 patients showing mild asthma with low healthcare use; class 3 patients showing severe asthma with severe exacerbation and airway obstruction; and class 4 patients showing poorly controlled asthma with frequent and severe exacerbation ([@B5]). Another study showed 4 subtypes presenting distinct clinical/biochemical findings in a Korean cohort using a 2-step cluster analysis based on 3 clinical phenotypes (urticaria, CRS and atopy status): subtype 1 (NERD with CRS/atopy and no urticaria), subtype 2 (NERD with CRS and no urticaria/atopy), subtype 3 (NERD without CRS/urticaria), and subtype 4 (NERD with acute/chronic urticaria exacerbated by NSAID exposure) ([@B55]). Each subtype had distinct features in the aspect of female proportion, the degree of eosinophilia, leukotriene (LT) E~4~ metabolite levels, the frequency of asthma exacerbation, medication requirements (high-dose ICS-LABA or systemic corticosteroids) and asthma severity, suggesting that stratified strategies according to subtype classification may help achieve better clinical outcomes in the management of NERD.

Pathophysiology {#s3}
===============

The major upper and lower airway symptoms of NERD are mediated by increased levels of CysLTs with dysregulation of arachidonic acid (AA) metabolism and intense type 2/eosinophilic inflammation ([@B20]).

CysLTs Overproduction {#s3_1}
---------------------

In the COX and LOX pathways, AA is metabolized to CysLTs (mostly LTE~4~, *via* 5-lipoxygenase \[5-LO\] and LTC~4~ synthase \[LTC4S\]), prostaglandin (PG) pathway (PGE~2~, PGF~2~, PGI~2~ and PGD~2~) and thromboxanes (TBX) A~2~ by PG synthase and TBX synthase ([@B90]), where enhanced synthesis of CysLTs synthesis with reduced level of PGE~2~ is a major finding in NERD ([@B70]; [@B71]; [@B56]; [@B107]). NERD patients have higher levels of CysLTs (especially LTE~4~) mainly derived from various inflammatory cells, including neutrophils, monocytes, and basophils, eosinophils and mast cells, which further increases after ASA/NSAID exposure compared to asthmatic patients with ASA/NSAID tolerance (ATA). Moreover, the increased expression of 5-LO and LTC4S was noted in NERD patients with overproduction of CysLTs; increased CysLTs bind to CysLT receptor 1/2, subsequently inducing bronchoconstriction and amplifying inflammatory signal pathways ([@B35]; [@B108]; [@B85]; [@B81]). Among PGs, PGE~2~/PGD~2~ play a major role in the pathogenesis of NERD. Increased PGD~2~ (released from mast cells and eosinophils) binds to prostanoid receptors to induce bronchoconstriction ([@B76]), and also binds to chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) to induce chemotaxis and activate eosinophils/basophils/Th2 cells/innate lymphoid cells (ILC2) ([@B33]; [@B105]), accelerating type 2 airway inflammation ([@B11]). The down-regulation of PGE~2~ biosynthesis, especially in peripheral blood leukocytes, nasal epithelial cells and nasal fibroblasts, was noted in patients with NERD ([@B50]; [@B9]; [@B71]). PGE~2~ has protective effects against bronchoconstriction, recruitment of eosinophils and degranulation of mast cells after binding to E prostanoid 2 (EP~2~) receptors ([@B27]; [@B87]); therefore, reduced levels of PGE~2~ in NERD cannot suppress the signal of 5-LO pathways through IL-10-dependent mechanisms ([@B30]). Furthermore, the lower expression of EP~2~ receptors is closely associated with abnormal regulation of the autocrine loop involved in COX pathways (IL-1R1, COX-2, mPGES) in NERD patients ([@B8]; [@B61]). This can be explained that COX-2 could not sufficiently produce PGH~2~ (the first unstable precursors of PG products from AA metabolism) without COX-1 ([@B95]). Therefore, reduction in PGE~2~ and its receptor levels could contribute to CysLTs overproduction in NERD patients. Lipoxin (LX) A4 and its epimer (15-epi-LXA4) are also called as the ASA-triggered lipoxins, and have antiinflammatory effects in airway inflammation ([@B71]; [@B83]). Their receptor termed formyl peptide receptor 2 (FPR~2~) is expressed on human neutrophils, eosinophils, macrophages, T cells, ILCs (ILC2 and NK cells) and epithelial cells of the respiratory tract. After binding their receptors, it leads to the restoration of epithelial barrier function and resolution of allergic inflammation through down-regulation of chemotaxis and cell activation ([@B3]; [@B83]). In the context of NERD, the concentration of LXA4 in the whole blood, sputum and bronchoalveolar lavage fluid, and 15-epi-LXA4 in the urine from NERD patients were lower than those in ATA patients. Additionally, their level has a negative correlation with worsening of airflow obstruction in patients with severe asthma ([@B18]; [@B78]; [@B49]; [@B106]). There was a significant increase in the FPR~2~ expression of NK cells and ILC2s from patients with severe asthma compared with those with milder asthma ([@B3]). All of the studies suggested that LXA4 and its epimer can be considered the potential therapeutics in the treatment of NERD ([**Figure 1**](#f1){ref-type="fig"}). NSAID-induced inhibition of the COX pathway leads to shunting of AA metabolism down the 5-LO arm ([@B65]; [@B23]). This is indirectly evidenced through the decreased level of antiinflammatory PG/LX (LXA~4~, 15-epi-LXA~4~, PGE~2~) and increased levels of the pro-inflammatory CysLTs ([@B18]; [@B78]; [@B30]; [@B49]; [@B106]).

![Mechanisms of airway inflammation in NERD. Increased levels of CysLTs and PGD~2~ as well as a decrease in the PGE~2~ level caused by the AA metabolism dysregulation are the main mechanism for promoting the severity of NERD. Released CysLTs, PGD~2~, and PGE~2~ regulate inflammatory cells *via* receptors expressed on individual cells (eosinophils, ILC2, mast cells, smooth muscle cells, granulocyte-adherent platelet, and neutrophils). These activated cells release cytokines, histamine, CysLTs, and PGD~2~, contributing to airway inflammation and remodeling in airway mucosa of NERD patients. 5-LO, 5-lipoxygenase; COX, cyclooxygenase; CysLTs, cysteinyl leukotrienes; PGs, prostaglandins; TBX, thromboxane; LT, leukotrienes; 15-HETE, 15-hydroeicosatetraenoic acid; FPR2, formyl peptide receptor 2; CysLTR, cysteinyl leukotrienes receptors; LTC4S, LTC4 synthase; EP2, E prostanoid 2; CRTH2, chemoattractant receptor-homologous molecule expressed on TH2 cells; TP receptors, T prostanoid receptors; IL, interleukin; TSLP, thymic stromal lymphopoietin; TSLPR, TSLP receptor; ILC2, innate lymphoid type 2 cells; Th2: T helper 2; ECP, eosinophil cationic protein; EDN: eosinophil-derived neurotoxin; IL5R, interleukin 5 receptor.](fphar-11-01147-g001){#f1}

Enhanced Type 2 Airway Inflammation {#s3_2}
-----------------------------------

NERD is characterized by persistent eosinophil activation (presenting severe asthma, CRS and NPs) and CysLTs overproduction in which increased CysLTs contributes to driving type 2 inflammatory responses ([@B56]; [@B75]; [@B92]). The key inflammatory cells in NERD are eosinophils and mast cells, which are closely interacting with other inflammatory and structural cells including basophils, platelets, neutrophils and epithelial cells. Regarding the activation mechanisms of eosinophils, both Th2 *cells* and ILC2 could activate eosinophils *via* release of IL-4, IL-5 and IL-13; moreover, activated eosinophils release the eosinophil extracellular traps (EETs), enhancing type 2 inflammation *via* interacting with epithelial cells and autocrine functions of eosinophils in the asthmatic airway ([@B71]; [@B17]; [@B107]). There have been some data demonstrating epithelial dysfunction related to type 2 inflammation in NERD: 1) lower levels of SPD (protective function against eosinophilia) ([@B16]), 2) increased epithelial folliculin and periostin levels ([@B41]; [@B93]; [@B17]), 3) increased CysLT-induced signaling (binding to CysLT2R or CysLT3R) in airway epithelial cells to induce the release of pro-inflammatory cytokines including IL-33, TSLP and IL-25 ([@B21]), leading to type 2/eosinophilic inﬂammation and remodeling in NERD ([@B96]).

Recent studies suggested that the activation of neutrophils may be related to the severity of airway inflammation in NERD ([@B44]), although the exact mechanism is still not fully elucidated. Increased LTB4 levels (mostly formed from neutrophils) and reactive oxygen species release after N-formyl-methionyl-leucyl-phenylalanine stimulation were noted in patients with NERD compared to ATA patients ([@B63]; [@B44]). In addition, platelets are activated by CysLTR2 on their surfaces to release IL33 and to interact with leukocytes through binding P-selectin (CD62P)--P-selectin glycoprotein ligand 1, GPIIb/IIIa-Mac-1 and CD40 ligand (CD40L)--CD40 ([@B51]; [@B64]; [@B59]; [@B92]). The activation of platelets and adherent leukocytes with platelets leads to the transmigration of leukocytes into inflammatory airway tissue with increased CysLTs, suggesting that platelet-aggregated granulocytes promote severe and persistent airway inflammation in NERD patients ([@B50]; [@B52]; [@B64]).

Genetic Mechanisms {#s3_3}
------------------

Many genetic studies have focused on CysLTs-related and eosinophil activating genes (major pathogenic mechanisms) according to single nucleotide polymorphisms (SNPs) and genome-wide association studies (GWASs) ([@B69]). ([**Table 1**](#T1){ref-type="table"}) *HLA* DPB1\*0301 has been regarded as a strong genetic marker and replicated in the 2 ethnic groups Polish and Korean populations ([@B22]; [@B13]). Patients suffering from this allele manifested the typical clinical characteristics of NERD, and had lower FEV1 levels and a higher prevalence of CRS and/or NPs ([@B13]). The GWAS demonstrated several significant SNPs (*HLA-DPB1*, rs3128965, *DPP10* rs17048175 in a Korean population, *TSLP* rs1837253 in a Japanese population, etc.) which were associated with the phenotypes of NERD ([@B68]; [@B42]; [@B43]). The genetic polymorphism studies identifying the SNPs related to CysLTs synthesis demonstrated several significant SNPs: the promoter polymorphisms at the *LTC4S* -444 A\>C in a Polish population ([@B77]), although it was not replicated in the other populations as the US, Japanese and Korean ([@B97]; [@B36]; [@B14]). The SNPs of G-coupled receptors (*CysLTR1* -634C\>T, -475 A\>C, -336 A\>G, *CysLTR2* -819 T\>G, 2078 C\>T, 2534 A\>G) lead to amplify the biological activity of CysLTs, the SNPs of prostanoid receptor genes (*PTGER2* -616 C\>G, -166 G\>A, *PTGER3* -1709 T\>A, *PTGER4* -1254 A\>G, *PTGIR* 1915 T\>A, *TBXA2R* -4684 C\>T, 795 T\>C) were associated with the development of NERD ([@B67]; [@B38]; [@B39]). Regarding the SNPs related to eosinophil activation, including those of the chemokine CC motif receptor (*CCR3* −520 T\>C), chemoattractant receptor molecular expressed in Th2 cells (*CRTH2* −466 T\>C) and *IL5R* (-5993 G\>A), were reported ([@B40]; [@B66]; [@B60]). Epigenetic factors, including exposure to NSAIDs and other stimuli, be also revealed to contribute to the development of NERD ([@B71]; [@B107]); DNA methylation associated with some SNPs (PGE synthesis, PGS, ALOX4AP, LTC4S, etc.) may contribute to presenting more severe phenotypes of NERD ([@B58]). Further replication studies in diverse ethnic groups are needed to clarify their functional roles in parallel with other omics markers with subphenotype classification.

###### 

Genetic polymorphisms associated with NERD.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                       Gene            SNP                                            Analysis methods                                             Ethnic group                   Patients                    OR (95% CI)                    *P*-value (compared with ATA)   Reference
  ------------------------------------ --------------- ---------------------------------------------- ------------------------------------------------------------ ------------------------------ --------------------------- ------------------------------ ------------------------------- -----------
  CysLTs overexpression                *LTC4S*         −444 A\>C                                      Amplified-fragment single-strand conformation polymorphism   Polish                         NERD: 47, ATA: 64, NC: 42   3.89\                          \<0.001                         ([@B77])
                                                                                                                                                                                                                              (1.57--8.98)                                                   

  *CysLTR1*                            −634 C\>T,\     Direct sequencing method                       Korean                                                       NERD: 105, ATA: 110, NC: 125   2.71\                       0.020                          ([@B38])                        
                                       −475 A\<C,\                                                                                                                                                (1.10--6.68)\                                                                              
                                       −336 A\<G                                                                                                                                                  2.89\                                                                                      
                                                                                                                                                                                                  (1.14--7.28)                                                                               

  *CysLTR2*                            −819 T\>G\      ABI PRISM 3700 DNA analyzer                    Korean                                                       NERD: 134, ATA: 66, NC: 152    2.04\                       0.031\                         ([@B67])                        
                                       2,078 C\>T\                                                                                                                                                (1.06--3.85)\               0.013\                                                         
                                       2,534 A\>G                                                                                                                                                 2.28\                       0.031                                                          
                                                                                                                                                                                                  (1.19--4.40)\                                                                              
                                                                                                                                                                                                  2.02\                                                                                      
                                                                                                                                                                                                  (1.07--3.84)                                                                               

  *PTGER2*                             −616 C\>G\      Direct sequencing                              Korean                                                       NERD: 108, ATA: 93, NC: 140    0.64\                       0.038\                         ([@B39])                        
                                       −166 G\>A                                                                                                                                                  (0.42--0.98)\               0.023                                                          
                                                                                                                                                                                                  2.60\                                                                                      
                                                                                                                                                                                                  (1.14--5.92)                                                                               

  *PTGER3*                             −1,709 T\>A     3.02\                                          0.043                                                                                                                                                                                  
                                                       (1.04--8.80)                                                                                                                                                                                                                          

  *PTGER4*                             −1,254 A\>G     1.77\                                          0.024                                                                                                                                                                                  
                                                       (1.08--2.90)                                                                                                                                                                                                                          

  *PTGIR*                              1,915 T\>A      0.41\                                          0.018                                                                                                                                                                                  
                                                       (0.20--0.86)                                                                                                                                                                                                                          

  *TBXA2R*                             −4,684 C\>T     0.42\                                          0.032                                                                                                                                                                                  
                                                       (0.19--0.91)                                                                                                                                                                                                                          

  795 T\>C                             0.67\           0.049\                                                                                                                                                                                                                                
                                       (0.45--1.00)\   0.032                                                                                                                                                                                                                                 
                                       2.57\                                                                                                                                                                                                                                                 
                                       (1.09--6.09)                                                                                                                                                                                                                                          

  Enhancement of type 2 inflammation   *CCR3*          −520 T\>C                                      MDR method                                                   Korean                         NERD: 94, ATA: 152          ND                             ND                              ([@B40])

  *CRTH2*                              −466 T\>C       Primer extension methods                       Korean                                                       NERD: 107, ATA: 115, NC: 133   ND                          0.044 (TT)\                    ([@B66])                        
                                                                                                                                                                                                                              0.037 (CC)                                                     

  *IL5R*                               −5,993 G\>A     Primer extension method                        Korean                                                       NERD: 139, ATA: 171, NC: 160   ND                          0.685 (GG)\                    ([@B60])                        
                                                                                                                                                                                                                              0.495 (AG)\                                                    
                                                                                                                                                                                                                              0.408 (AA)                                                     

  Others                               *HLA*           DPB1\*0301                                     DNA methods                                                  Polish                         NERD: 59, ATA: 57, NC: 48   5.3\                           \<0.001                         ([@B22])
                                                                                                                                                                                                                              (1.90--14.40)                                                  

  ABI 3100 Genetic analyzer            Korean          NERD: 76, ATA: 73, NC: 91                      5.2\                                                         0.004                          ([@B13])                                                                                   
                                                                                                      (1.80--14.70)                                                                                                                                                                          

  *HLA-DPB1*                           rs3128965       Affymetrix Genome-Wide Human SNP array         Korean                                                       NERD: 264, ATA: 387, NC: 238   1.8\                        0.098 (AG)\                    ([@B42])                        
                                                                                                                                                                                                  (1.22--2.68)\               0.001 (AA)                                                     
                                                                                                                                                                                                  3.1\                                                                                       
                                                                                                                                                                                                  (094--10.70)                                                                               

  *HLA-DPB1*                           rs104215        GoldenGate assay with the VeraCode microbead   Korean                                                       NERD: 117, ATA: 685            2.40\                       \<0.001 (fine-mapping study)   ([@B68])                        
                                                                                                                                                                                                  (1.68--3.42)                                                                               

  *DPP10*                              rs17048175      Affymetrix Genome-Wide Human SNP array         Korean                                                       NERD: 139, ATA: 171, NC: 160   ND                          0.083 (TT)\                    ([@B43])                        
                                                                                                                                                                                                                              0.072 (CT)\                                                    
                                                                                                                                                                                                                              0.022 (CC)                                                     
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NERD, NSAID-exacerbated respiratory disease; ATA, aspirin-tolerant asthma; CysLTR, cysteinyl leukotriene receptor; LT, leukotriene; PG, prostaglandin; TX, thromboxane; CRTH2, chemoattractant receptor homolog expressed by type 2 helper T cells; CCR, chemokine receptor; HLA, human leukocyte antigen; DPP, dipeptidyl peptidase; IL, interleukin; ND, no data.

Diagnosis {#s4}
=========

A diagnosis of NERD is fundamentally based on the patient's history. NERD is suspected in patients having a history of upper/lower respiratory reactions after ingestion of ASA/NSAIDs or suffering from asthma along with CRS and NPs, ([@B15]). Some patients have a definitive history of adverse reactions to ASA/NSAIDs: however, many patients have not experienced hypersensitivity reactions ([@B65]). One study showed that 14% of patients who thought they had NERD based on symptoms were negative for oral aspirin challenge ([@B25]). Thus, ASA challenge, as the gold standard for diagnosing NERD, is required to confirm or exclude hypersensitivity in patients with unclear history of adverse reactions.

There are 3 types of the ASA challenge test *via* the oral, bronchial and nasal routes. The oral challenge test is a more commonly used and convenient approach compared to other challenge tests in that it mimics natural exposure ([@B1]). It may be more suitable for investigating systemic adverse reactions to NSAIDs. Bronchial challenge with lysine-aspirin is safer and quicker, but shows lower sensitivity than the oral test. Nasal challenge is recommended for patients with predominant nasal symptoms, but the sensitivity is lower ([@B56]; [@B48]). The EAACI recommended the oral challenge protocol with starting 20-40 mg of aspirin and gradually increasing the dose at 2 hour intervals. When no reactions occur within 3 hours after 325 mg of aspirin, the challenge is considered to be negative ([@B48]). Patients with lower FEV1 (\<70% of the predicted value) or unstable asthma status are not recommended, and the test should be performed in a hospital with resuscitative equipment under the supervision of special training physicians ([@B1]). These tests may be influenced by bronchial hypersensitivity, ASA dosage, and the concurrent use of leukotriene modifier drugs and antihistamines ([@B102]; [@B103]). When patients are false-negative for ASA challenge, subsequent confirmatory challenges are recommended for holding leukotriene modifier drugs, antihistamines and oral corticosteroids for at least 1 week and employing high-dose ASA challenges ([@B104]).

There is no *in vitro* test available for the diagnosis of NERD. LTE~4~ (especially in urine) is suggested to be the most reliable biomarker for the diagnosis of NERD. Several studies demonstrated that patients with NERD had higher baseline concentrations of urinary LTE~4~ as well as greater increase after aspirin/NSAID exposure than in patients with ATA, suggesting that urine LTE~4~ level could be used as a clinical diagnostic test ([@B29]; [@B6]). Recent studies demonstrated higher levels of serum periostin, and folliculin as potential biomarkers of NERD, however, further validation studies are needed in other cohorts ([@B41]; [@B93]). The Polish group proposed the Aspirin-Sensitive Patients Identification Test (ASPI Test), however, it was not replicated in other centers ([@B46]). Despite the basophil activation test (BAT) has been investigated for *in vitro* diagnosis of NERD, variable values of sensitivity and specificity were reported depending on the protocols used, remaining limitations of the clinical use ([@B80]). More efforts are needed to establish *in vitro* diagnostic tests for reducing the risks of challenge tests with identifying reliable biomarkers for the diagnosis of NERD and the classification of its subphenotypes.

Management {#s5}
==========

The standard management of NERD involves the guidelines established for the management of asthma and CRS with ASA/NSAID avoidance. The complete avoidance of culprit agents and cross-reacting NSAIDs with use of alternative agents (highly selective COX-2 inhibitors such as celecoxib, and partial inhibitors such as acetaminophen, meloxicam or nimesulide) is essential. ASA desensitization can be beneficial for NERD patients when indicated.

Pharmacologic Treatment {#s5_1}
-----------------------

Treatment strategies for asthma should follow stepwise management guidelines with maintaining inhaled corticosteroids with or without long-acting beta 2 agonists, leukotriene modifier drugs and/or biologic agents on the basis of disease severity and rescue medications ([@B28]). Because the overproduction of CysLTs is a key feature in the pathogenic mechanisms, targeting the leukotriene pathway with CysLT1 receptor antagonists (montelukast, zafirlukast and pranlukast) and 5-LO inhibitors (zileuton) should be considered to improve upper and lower airway symptoms. Several studies have shown that these leukotriene modifiers lead to improvement in asthma symptoms, pulmonary function, quality of life, nasal function and lower use of bronchodilators ([@B74]).

Initial treatment for CRS includes intranasal corticosteroids with intranasal saline irrigation. Intranasal corticosteroids have shown to be highly effective in reducing nasal inflammation and in shrinking NPs, which are recommended as a first-line treatment in patients with CRSwNP ([@B15]; [@B82]; [@B74]). Because rinsing the nasal cavities with saline is helpful in removing secretions and washing away allergens and irritants, nasal irrigation prior to administration of topical medications can improve the response to the medications ([@B82]; [@B74]). Systemic corticosteroids and broad-spectrum antibiotics can be additionally required according to the severity of nasal symptoms. Adding antihistamines or oral/nasal decongestants may provide symptom relief ([@B1]).

Despite the heterogeneity of NERD, therapeutic approaches have been proposed according to symptom severity. However, these different phenotypes contribute to the variability in response to treatment. A recent study found that clinical severity and courses differ among the 4 subtypes of NERD, which affect antiasthmatic medications required ([@B55]). Subtype 1/2 patients had severe clinical courses, requiring higher-dose of antiasthmatic medications including higher dose of ICS and systemic corticosteroids, while subtype 3 patients required low doses of these drugs with less frequent asthma exacerbation. These results suggest that a personalized approach according to subtype classification is needed to achieve better outcomes in the management of NERD.

ASA Desensitization {#s5_2}
-------------------

ASA desensitization is an effective treatment option when standard medical treatments are not effective or daily ASA/NSAIDs therapy is required for other medical conditions, such as coronary artery disease or chronic inflammatory disease ([@B86]). Multiple studies have demonstrated the effectiveness of ASA desensitization in reducing NP size and the need for sinus surgery as well as in improving nasal and bronchial symptoms with decrease in the doses of topical and oral corticosteroids ([@B88]; [@B98]). A recent study showed the long-term safety and efficacy of ASA desensitization in patients who underwent continuous daily ASA therapy for more than 10 years ([@B99]). ASA desensitization is a provocative procedure by starting at low doses of ASA and gradually increasing to the dose of 650 to 1300 mg over a period of 1 to 3 days, which can induce hypersensitivity reactions ([@B101]). Thus, as safety is an important issue, ASA desensitization should be carried out in a well-equipped hospital under the supervision of special training physicians. The protocol with gradually increasing the dose over 2 days was suggested by the EAACI to secure safety and efficacy of aspirin desensitization ([@B48]).

Biologics {#s5_3}
---------

The emergence of biologics in the management of asthma and CRSwNP has represented potential and promising therapy for NERD. New biologics targeting type 2 cytokines, such as IL-4, IL-5 and IL-13 as well as IgE, have been reported in clinical trials, which could reduce asthma exacerbation and oral corticosteroid use, and improve lung function ([@B37]; [@B62]). In addition, they have been shown to improve nasal symptom severity and reduce NP size in patients with CRSwNP, leading to a significant increase in quality of life ([@B2]). Because NERD is strongly associated with mast cell activation and eosinophilic airway inflammation, the efficacy of biologics may be different from those usually observed in severe asthma ([@B31]). Here, we summarized the available studies for these biologics in patients with NERD ([**Table 2**](#T2){ref-type="table"}).

###### 

Biologics in NERD patients: Summary of available studies.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Biologics(Target)   Study design(Number of participants)                  Route, Dose and Study period                                                                      Efficacy outcomes                                                                                                                              Reference
  ------------------- ----------------------------------------------------- ------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------- -----------
  Omalizumab\         Double-blind, randomized, placebo-controlled trial\   Subcutaneous injection every 2 or 4 weeks based on total IgE level and body weight for 3 months   Improvement in ACT, ACQ-6, SNOT-22 and VAS scores in omalizumab group compared with placebo group after 3-month treatment. (All, *P*\<.001)\   ([@B32])
  (IgE)               (16 Omalizumab vs. 16 Placebo)                                                                                                                          Improvement in FEV1 (%) in omalizumab group compared with placebo group after 3-month treatment (*P*=.003)                                     

  Omalizumab\         Retrospective analysis\                               Subcutaneous injection for 1 year                                                                 Reduction in use of OCS and SABA during 1 year on omalizumab treatment compared with 1 year before initiating omalizumab. (All, *P*=.001)      ([@B34])
  (IgE)               (29 Omalizumab)                                                                                                                                                                                                                                                                                        

  Dupilumab\          *Post hoc* analysis\                                  Subcutaneous injection of 300 mg weekly for 16 weeks                                              Improvement in NPS, ACQ-5 and SNOT-22 total scores in dupilumab group compared with placebo group after 16-week treatment (All, *P*\<.005)\    ([@B53])
  (IL-4Rα)            (8 Dupilumab vs. 11 Placebo)                                                                                                                            Changes in FEV1 (L) from baseline in dupilumab group compared with placebo group after 16-week treatment. (*P*\<.05)                           

  Mepolizumab\        Retrospective analysis\                               Subcutaneous injection of 100 mg every 4 weeks for 3 months                                       Reduction in absolute eosinophil count from baseline after 3-month treatment. (*P*=.001)\                                                      ([@B94])
  (IL-5)              (14 Mepolizumab)                                                                                                                                        Improvement in SNOT-22 and ACT scores from baseline after 3-month treatment. (*P*=.005 and *P*=.002, respectively)\                            
                                                                                                                                                                              No significant improvement in FEV1 (%) from baseline (*P*=.16)                                                                                 

  Reslizumab\         *Post hoc* analysis\                                  Intravenous injection of 3 mg/kg every 4 weeks for 52 weeks                                       Difference in frequency of asthma exacerbation in reslizumab, 0.29 vs placebo, 1.95 (*P*=.001) during 52-week treatment.\                      ([@B100])
  (IL-5)              (28 Reslizumab vs. 28 Placebo)                                                                                                                          Changes in FEV1 (L) from baseline in reslizumab, 0.327L vs placebo, 0.002L (P\<.001) after 52-week treatment.                                  
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IL, interleukin; IL-4Rα, interleukin-4 receptor alpha subunit; ACT, asthma control test; ACQ-6, 6-item asthma control questionnaire; SNOT-22, 22-item sino-nasal outcome Test; VAS, visual analog scale; OCS, oral corticosteroid; SABA, short-acting β2 agonist; NPS, nasal polyp score; ACQ-5, 5-item asthma control questionnaire.

Omalizumab, a humanized recombinant monoclonal anti-IgE antibody, prevents IgE from binding to its high-affinity receptor and reduces Fc receptor expression on mast cells and basophils, subsequently suppressing their activation ([@B12]). Several studies have suggested the efficacy of omalizumab in the management of NERD, demonstrating a reduction in asthma exacerbation and the need for systemic steroids and short acting beta-2 agonist (SABA) as well as an improvement in upper and lower airway symptoms ([@B31]; ([@B57]; [@B34]). Furthermore, there are some studies suggesting that omalizumab treatment can be beneficial for reducing respiratory symptoms during ASA desensitization and even can restore ASA tolerance without the need for ASA desensitization ([@B72]; [@B54]; [@B32]). Omalizumab could improve upper and lower airway symptoms with suppression in urinary markers of mast cell activation, LTE~4~ and PGD~2~ metabolites, in patients with NERD and lead to the development of ASA tolerance with a reduction in urinary LTE~4~ concentrations during oral ASA challenge ([@B31]; [@B32]), suggesting that omalizumab has inhibitory effects on mast cell activation in NERD.

Dupilumab is a human monoclonal antibody that targets the IL-4α receptor and inhibits signaling of both IL-4 and IL-13. Although the study was conducted in a small number of patients with NERD, dupilumab could improve nasal and asthma-related symptom scores and lung functions ([@B53]), although studies with a larger sample size are needed to confirm its effectiveness. Mepolizumab and reslizumab are both monoclonal antibodies that prevent IL-5 from binding to its receptor on eosinophils, and benralizumab is a monoclonal antibody that targets the alpha subunit of the IL-5 receptor. The respiratory tract of NERD patients is characterized by intense eosinophilic inflammation, with higher levels of eosinophils in NPs and bronchial mucosa biopsies than in ATA patients ([@B94]; [@B26]). These biologics inhibiting IL-5, eosinophilic maturation and differentiation factor could be effective in the management of patients with NERD ([@B14]). In addition, based on recent study results on the pathogenic mechanisms, P2Y12 receptor antagonists, CRTH2 antagonists and anti-TSLP/IL-33 antibodies could be potential options in the management of NERD patients ([@B74]).

Considering the heterogeneity of NERD phenotypes/endotypes, selecting right patients and right targets (biologics) are essential in the management of NERD. In phenotypic clusters of NERD, subtype 4 patients (NERD with urticaria) would need omalizumab as an effective option, which can inhibit activated basophils and mast cells, the key elements of NERD and urticaria ([@B55]); subtype 2 patients with severe eosinophilia may need anti-IL-5 as a first option. Despite the development of biologic therapies, unmet needs remain in NERD patients to be understood with regard to their comparative efficacy and long-term safety. Further studies are needed to answer questions on the selection of right patients and targets with right safety.

Dietary Interventions {#s5_4}
---------------------

Dietary intervention may be beneficial for controlling symptoms in patients with NERD. Some studies demonstrated that restricting dietary salicylates, including fruits, vegetables, berries, herbs, and spices, improves nasal and asthmatic symptoms, which can be explained by the known contribution of salicylates in the pathogenesis ([@B91]; [@B84]). A previous study showed that alcohol ingestion can more commonly lead to upper and lower respiratory reactions in NERD patients, although the underlying mechanism is not clear ([@B10]). Thus, restricting the diet, when experienced respiratory symptoms after the ingestion, can be additionally effective.

Conclusion {#s6}
==========

Patients with NERD present with a variety of clinical features affected by chronic type 2 eosinophilic inflammation with the overproduction of CysLTs in the upper and lower airways. Although NERD tend to be associated with severe asthma and CRSwNP, an improved understanding of clinical features and underlying pathogenesis of NERD will aid in diagnostic evaluations and new therapeutic strategies for improving clinical outcomes. With the increasing recognition of phenotypic heterogeneity of NERD, efforts are needed to establish precision medicine strategies tailored to individual phenotypes/endotypes with potential biomarkers.

Author Contributions {#s7}
====================

The clinical features, diagnosis and treatment of NERD were described by S-DW and the pathophysiologic mechanisms including molecular genetic mechanisms were described by QL. This article was written under supervision of H-SP. She, as corresponding author, performed the overall design and review of this article.

Funding {#s8}
=======

This study was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health & Welfare, Republic of Korea (H116C0992).

Conflict of Interest {#s9}
====================

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

[^1]: Edited by: Tahia Diana Fernández, University of Málaga, Spain

[^2]: Reviewed by: Craig R. Lee, University of North Carolina at Chapel Hill, United States; M. Isabel Lucena, University of Malaga, Spain

[^3]: This article was submitted to Pharmaceutical Medicine and Outcomes Research, a section of the journal Frontiers in Pharmacology
